Background. Treatment of second-stage sleeping sickness relies mainly on melarsoprol. Nifurtimox has been successfully used to cure melarsoprol-refractory sleeping sickness caused by Trypanosoma brucei gambiense infection.
invaded the central nervous system (CNS), is fatal if left untreated. Treatment relies mainly on melarsoprol, a combination of the trivalent organic arsenical melarsen oxide and the heavy metal chelator dimercaprol, and is associated with severe adverse events. The mechanisms of action of melarsoprol are not well understood. Empirically established regimens differ considerably. Only recently has a randomized trial, based on better knowledge of pharmacokinetics, demonstrated the effectiveness of a concise 10-day intravenous (iv) regimen [1, 2] .
Eflornithine and nifurtimox are also able to cure second-stage sleeping sickness, including cases that are refractory to melarsoprol treatment [3, 4] . Eflornithine, an inhibitor of ornithine decarboxylase, causes a de-pletion of polyamines in trypanosomes [5] ; iv eflornithine is registered for sleeping sickness treatment, but its production is complicated, costly, and had been interrupted at the time of the present trial. Nifurtimox, developed and registered for Chagas disease therapy, is a 5-nitrofuran. It has been successfully used for the treatment of melarsoprol-refractory T. brucei gambiense infection. Its activity relies on the membrane and DNA binding of free radicals generated by nitrofuran reduction [6] . A standard regimen has not yet been established, nor has its effectiveness been randomly compared with that of melarsoprol. Among the schedules used in open trials and for compassionate treatment [4, [7] [8] [9] [10] [11] , the following nifurtimox regimen has been recommended: 5 mg/kg and 7 mg/kg 3 times a day (every 8 h) for adults and children, respectively, for 14-21 days [4] .
Increased treatment-failure rates with melarsoprol have been reported in Angola, Uganda, and Sudan, and primary resistance may occur [12] [13] [14] [15] . Consequently, it is urgent to optimize monotherapy with current antitrypanosomal drugs, on the basis of improved knowledge of their pharmacokinetics, and to investigate the effectiveness and toxicity of drug combinations [4, 9, 14, [16] [17] [18] . We present here the results of a randomized clinical trial intended to assess the equivalence between standard melarsoprol therapy, 10-day incremental-dose melarsoprol therapy, 14-day nifurtimox monotherapy, and combination therapy consisting of 8 days of nifurtimox and 10 days of lowdose melarsoprol.
PATIENTS, MATERIALS, AND METHODS

Study design.
The study was designed to test for equivalence between the standard melarsoprol regimen and 3 other regimens. Block randomization was prepared before the study was begun. Regimens and modes of administration were too different to allow blinding. Primary outcomes were relapse, severe adverse events, and death attributed to treatment. Secondary outcomes were frequency of other adverse events.
Patients. Patients were recruited from the area around Bwamanda Hospital, Equateur Province, Democratic Republic of Congo (DRC), where sleeping sickness was epidemic at the time of the study. More than 1 million people were at risk, and mobile teams screening 456,141 individuals detected 13,913 new cases in 1998 [19] . Inclusion criteria were age 115 years, parasitologically confirmed second-stage T. brucei gambiense infection, and no history of treatment for sleeping sickness. Exclusion criteria were Glasgow coma score !8, pregnancy, active tuberculosis, positive serological result for syphilis, bacterial or cryptococcal meningitis, severe anemia, severe renal or hepatic dysfunction, hemorrhagic cerebrospinal fluid (CSF), and residence 1100 km from Bwamanda. Patients were informed about the trial objectives and modalities and were asked to provide consent. The study protocol was approved by the Ministry of Health, Kinshasa, DRC.
Diagnosis. Individuals were screened for the presence of specific antibodies by use of the card agglutination test for trypanosomiasis (CATT) [20] . Persons who were seropositive by CATT or who presented with suggestive clinical signs were examined for trypanosomes in the blood (stained thick smear and capillary tube centrifugation), lymph node aspirate, and CSF. The examination of CSF from patients with parasitologically confirmed T. brucei gambiense infection was done to determine the disease stage (white blood cell [WBC] count, trypanosome search during WBC count and after double centrifugation, IgM titration by latex agglutination assay, and protein quantification) [21] [22] [23] . Second-stage disease was defined as either (1) CSF WBC count 120 cells/mL and detectable IgM in CSF (IgM titer у1) or (2) detection of trypanosomes in CSF. Clinical, neurological, psychiatric, and endocrinological data were recorded 3 days before treatment. These examinations, except for the CSF IgM assay and CATT, were repeated 24 h after the last drug administration. Examinations for coinfections (malaria, filariasis, and syphilis), anemia, and renal, hepatic, and pancreatic dysfunction were performed before treatment.
Treatment. Before administration of the specific treatment, all patients received pretreatment for 3 days with chloroquine base (600 mg on each of the first 2 days and 300 mg on the final day) and mebendazole (100 mg twice a day). Four trypanosomiasis-specific regimens were tested: (1) Standard melarsoprol therapy as administered in the DRC-3 series of 3.6 mg/kg/day iv for 3 days, with 7-day breaks between the series (maximum of 180 mg/day; total dose, 32.4 mg/kg); (2) 10-day incremental-dose melarsoprol therapy-0.6 mg/kg iv on day 1, 1.2 mg/kg iv on day 2, and 1.8 mg/kg iv on days 3-10 (maximum of 90 mg/day; total dose, 16.2 mg/kg); (3) nifurtimox monotherapy-5 mg/kg given orally, under nurse supervision, every 8 h for 14 days (total dose, 210 mg/kg); and (4) consecutive 10-day melarsoprol-nifurtimox low-dose combination therapy-2 days of melarsoprol alone (0.6 mg/kg iv on day 1 and 1.2 mg/kg iv on day 2), followed by 8 days of 7.5 mg/kg oral nifurtimox every 12 h combined with melarsoprol at 1.2 mg/kg/day (total melarsoprol dose, 11.4 mg/kg; total nifurtimox dose, 120 mg/kg).
No concomitant corticosteroid treatment was systematically administered to patients. Drug tolerance was assessed daily. Clinical events were classified as adverse if they occurred during or up to 7 days after treatment. Events leading to premature termination or temporary suspension of treatment were classified as severe. Encephalopathic syndromes included encephalopathy and suspicion of encephalopathy. Encephalopathy was defined as a decrease in consciousness and tonus with or with- out convulsions. Suspicion of encephalopathy was defined as an association of several of the following: apathy, high fever, urticaria, vomiting, tremor, and convulsions. Encephalopathic syndromes were treated with steroids (iv bolus injections of 1 mg/kg dexamethazone for 2-3 days) [24] . Other adverse events were treated symptomatically with appropriate drugs (mainly paracetamol, polaramine, diazepam, indomethacine, aspirin, and vitamin B6). Episodes of symptomatic malaria were treated with iv quinine or sulfadoxine-pyrimethamine.
Follow-up. Follow-up assessments were scheduled at 3, 6, 12, 18, and 24 months after treatment. They consisted of clinical examinations; microscopic examinations of lymph node aspirate, blood, and CSF; measurements of CSF protein concentrations and WBC counts; and screening for coinfections. Pa- tients who did not appear for a follow-up assessment were actively traced.
Patients who met the following criteria were classified as having experienced a relapse (hereafter, "relapse patients"): (1) detection of trypanosomes at any follow-up assessment; (2) no detection of trypanosomes at interim follow-up assessments but a CSF WBC count 120 cells/mL and at least twice as high as the previous follow-up result; or (3) no detection of trypanosomes у24 months after treatment but a CSF WBC count 120 cells/mL.
Statistical analysis. The analysis was designed to compare each new regimen (10-day incremental-dose melarsoprol therapy, 14-day nifurtimox monotherapy, and 10-day melarsoprolnifurtimox combination therapy) with the reference regimen (standard melarsoprol therapy). An estimated sample size of 650 was necessary to prove equivalence (a, 5%; , 80%; 1 Ϫ b D, 15%; and adjustment for 40% loss to follow-up). The difference in relapse rates between the reference regimen and each of the other regimens was taken as effectiveness criterion. Analysis was done on an intention-to-treat basis. Descriptive analysis was done using proportions for qualitative variables and medians or for quantitative variables. Pearson's x 2 means ‫ע‬ SD test or Fisher's exact test was used to test differences in proportions. Means were compared using Student's t test, and distributions were compared using the Mann-Whitney U test or the Kruskal-Wallis test. Relapse rates were estimated using survival analysis by the Kaplan-Meier method and were then compared using log-rank tests. Each of the rates in the 3 new regimens was compared with the corresponding rate in the reference regimen. The level of significance was fixed to P р in all analyses. .05
RESULTS
Study population and compliance. Figure 1 summarizes the study results. A total of 278 patients were enrolled between February and August 1998; 69 were assigned to receive standard melarsoprol therapy (group A); 70 to receive 10-day incremental-dose melarsoprol therapy (group B); 70 to receive 14-day nifurtimox monotherapy (group C); and 69 to receive 10- (table 1) . The full prescribed dosage was P 1 .05 given to 258 patients, of whom 111 deviated from the schedule because of either adverse events (12 in group A, 20 in group B, 16 in group C, 16 in group D) or bad compliance (patient was absent from the ward at the moment of drug administration; 12 in group A, 3 in group B, 9 in group C, and 23 in group D). Treatment was prematurely terminated (incomplete treatment) in 18 patients. Nine of these died during treatment-2 of encephalopathy in group B and 7 as a consequence of bad general health that existed before treatment. The 9 surviving patients did not complete treatment because of severe adverse events, bad compliance, or coinfection. Two patients in group A left the hospital before the end of treatment assessment, and their files were lost.
Therapeutic response and follow-up. Twenty-four hours after the end of treatment, no trypanosomes were detected in any of the patients assessed. Except for 3 patients who died within 18 days of the end of treatment, the clinical condition of the patients in all groups had improved. Figure 1 summarizes the patient's compliance with follow-up.
Relapse. Relapses ( ) were observed with all of the n p 48 monotherapy regimens (7 in group A, 17 in group B, and 24 in group C) but not with melarsoprol-nifurtimox combination therapy. In group C (nifurtimox monotherapy), trypanosomes were found during follow-up in the blood of 11 patients, of whom 4 had a CSF WBC count р5 cells/mL and 2 had a CSF WBC count of 6-9 cells/mL. Trypanosomes were not detected in the blood or lymph of any of the relapse patients in the other groups, but their CSF results fitted the definition of relapse (31 patients were trypanosome positive in CSF, and 6 patients who were negative for trypanosomes had a CSF WBC count that was 120 cells/mL and that had doubled since the previous follow-up assessment). Within each group, there were no differences in the frequency of relapses between patients who deviated from the schedule but completed treatment and those who did not. The proportion of relapses was significantly lower for the melarsoprol-nifurtimox regimen than for the standard melarsoprol regimen or for any other regimen ( ). P p .01 Of the monotherapy regimens, the standard melarsoprol regimen was significantly more effective than the others ( ). Kap-P p .01 lan-Meier curves confirmed the superior effectiveness of the melarsoprol-nifurtimox combination regimen (figure 2). To be able to calculate the log rank in the melarsoprol-nifurtimox arm, we added 1 notional relapse patient to group D and could still show a significant difference ( ). P p .02 Deaths. After treatment, deaths occurred in all groups but C (nifurtimox monotherapy) (figure 1). After receipt of standard melarsoprol therapy (group A), 1 emaciated and psychotic patient, who refused to eat, died in the hospital 3 days after treatment; 1 died of encephalopathy 18 days after treatment (with onset during treatment); and 3 died several months after treatment either with symptoms that were possibly due to sleeping sickness (1 patient) or after persistent sleep disturbances (2 patients). After incremental-dose melarsoprol therapy (group B), 1 patient died 2 months after treatment due to bad general health; 2 died 16 months after treatment due to persisting bad (Fisher's exact test) . P p .007 general health; and 3 died 18 months after treatment due to causes unrelated to treatment (cirrhosis, jaundice, and accidental fall). After melarsoprol-nifurtimox combination therapy (group D), 1 patient died of encephalopathy 7 days after treatment; 1 was in bad general health at enrollment and died 5 months after treatment; and 1 died 11 year after treatment with symptoms that were possibly due to sleeping sickness. There was a significant difference in the frequency of after-treatment death between the standard melarsoprol regimen and nifurtimox monotherapy ( ) but not between the standard P p .03 melarsoprol regimen and both other melarsoprol-containing regimens.
Adverse events and toxicity. During treatment, 387 adverse events were observed (table 2). Phlebitis was significantly more frequent with standard melarsoprol therapy than with nifurtimox monotherapy ( ) or with melarsoprol-nifurti-P ! .0001 mox combination therapy ( ). No other adverse event P ! .007 was significantly related to any particular regimen compared with another regimen. Encephalopathic syndromes occurred in all treatment groups and were fatal in 4 patients. The most frequent other severe adverse events were vomiting, for nifurtimox monotherapy (11 patients); fever, for the melarsoprolcontaining regimens (4 patients in group A, 7 in group B, and 6 in group D); and urticaria, for the incremental-dose melarsoprol regimen (3 patients).
DISCUSSION
The results of an open, randomized clinical trial in previously untreated patients with parasitologically confirmed secondstage T. brucei gambiense sleeping sickness are reported here. The required sample size could not be reached because of premature trial termination due to political instability in the area. Nevertheless, the trial shows the superior effectiveness of a concise, consecutive low-dose melarsoprol-nifurtimox combination versus 3 monotherapy regimens, including the standard melarsoprol regimen.
No relapses were observed with melarsoprol-nifurtimox combination therapy. Relapses occurred in all other treatment groups, and adverse events were not significantly different. Our relapse rate of 10.1% after the standard melarsoprol regimen is similar to rates (up to 15%) observed during control activities in the same area. The relapse rate of 24.3% after our 10-day incremental-dose melarsoprol regimen is higher than the rates of 6% and 14% observed in other trials of a concise, consecutive 10-day melarsoprol regimen of 2.2 mg/kg/day [2, 25] . This may be due to the progressive dose increase and lower daily dosage in our regimen resulting in insufficient melarsoprol levels in the CNS or to the difference in patient characteristics. Our higher CSF WBC count cutoff (120 cells/mL instead of 15 cells/ mL in the other study [1] ) was deliberately chosen to avoid the enrollment of patients who might still be curable with firststage drugs [26] .
Although the number of enrolled patients was too low to draw unequivocal conclusions, the results seem to favor neither our 10-day incremental-dose melarsoprol regimen nor our 14-day nifurtimox monotherapy regimen for first-line treatment of second-stage T. brucei gambiense sleeping sickness. Interestingly, trypanosomes were detected in the blood of 6 patients who relapsed after nifurtimox monotherapy, whereas no trypanosomes were detected in their CSF, and their CSF WBC counts were either normal or close to normal (!10 cells/mL). Reinfection cannot be excluded but is unlikely, given that a similar phenomenon was not observed in the other treatment groups. Nifurtimox may not have reached sufficient levels in some peripheral body compartments or perhaps is less active on blood than on CSF trypanosomes.
The frequency of adverse events was not significantly higher with any regimen, except for phlebitis at the injection site for the standard melarsoprol regimen compared with nifurtimox monotherapy, which was to be expected because nifurtimox is administered orally. That no other significant differences in adverse events were observed may be due to the insufficient number of enrolled patients. Encephalopathic syndromes occurred with all regimens; thus, they cannot be exclusively attributed to melarsoprol, as has been reported [9, 27] . Causal mechanisms unrelated to inherent drug toxicity are likely involved, including immune reactions and coinfections [28] . The rates of severe adverse events, particularly of encephalopathic syndromes and mortality likely due to treatment, were within the range observed in other studies [1] , although we did not administer corticosteroids concurrently. Encephalopathy with fatal outcome was observed only with the 3 melarsoprol-containing regimens. However, the insufficient number of enrolled patients does not allow us to conclude unequivocally that this was due to inherent melarsoprol toxicity.
Clinical criteria for the assessment of disease severity are not well established. In the present study, 2.9% of the patients died during or within 7 days after treatment for no other obvious reason than their advanced disease stage and bad general health at enrollment. Apparently, the exclusion criterion of a Glasgow coma score !8 does not prevent the enrollment of moribund patients [29] . Other coma scales may be more appropriatefor example, the Karnofsky scale (based on patient disabilities), which was used in a recent trial in Uganda [30, 31] .
The present trial is the first to show that a concise, consecutive 10-day low-dose melarsoprol-nifurtimox combination can cure second-stage T. brucei gambiense sleeping sickness and that this regimen is significantly more effective than the 3 studied monotherapy regimens, including the standard melarsoprol regimen. The total doses of each drug in the combination are the lowest ever reported for the treatment of second-stage sleep-ing sickness, and the significantly superior effectiveness of this regimen suggests that a synergism exists between melarsoprol and nifurtimox. The melarsoprol-nifurtimox combination is easy to administer, and, compared with the standard melarsoprol regimen, the treatment duration is shorter and the treatment costs are lower. Moreover, the combination of 2 antitrypanosomal drugs is likely to delay the development of drug resistance.
